Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
about
Enhancement of mouse germ cell-associated genes expression by injection of human umbilical cord mesenchymal stem cells into the testis of chemical-induced azoospermic mice.Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.Myeloablative conditioning regimens for AML allografts: 30 years later.Safety of conditioning agents for allogeneic haematopoietic transplantation.Busulfan in hematopoietic stem cell transplant setting.Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back.The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.Accidental busulfan overdose during conditioning for stem cell transplantation.Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation.Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists.Molecular effect of human umbilical cord blood CD34-positive and CD34-negative stem cells and their conjugate in azoospermic mice.Intravenous busulfan dose individualization - impact of modeling approach on dose recommendation.Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation
P2860
Q34433197-EB1D606D-6B37-4667-AB58-0696148414C5Q35202316-ADC403F3-45E2-47F7-A85A-8EDF0005EDC7Q35574536-86B14885-C415-40A2-8349-D023E00DA18CQ37510948-B4813151-553F-42DC-A199-1EA5FD5D7089Q37554387-16C22F3E-71EE-4338-8DAE-62A21BC880A9Q38029953-F944587A-367A-47D0-9283-5A7163CB490AQ39005626-1F1AC6E9-9E36-4AE0-A6FC-BEC6A2A4251AQ43429437-5AF864AE-BE59-41DE-909F-202AD0FBAA1BQ44117304-0E9C0FA1-CB5E-4B19-8AB9-877B7FF3332EQ44383228-139525E0-C704-435F-ABEE-BBAE89D1F8A2Q44830422-7CAA31C2-DD1C-403C-8E89-1755124E64BEQ45122639-4DF53184-E3B4-4796-84C1-814D4FB07213Q45165351-13C43DC4-1A72-417B-8C29-8A5C5CCD4C80Q46366072-68279D55-D4F3-4339-A857-25B2556FCDE5Q46847077-51789AC1-4313-4391-9F12-D163D762DE63Q46958507-70FE0B54-4820-45B7-812D-CDE41BDB183BQ47589580-292156AF-DCA0-4A67-98C0-F09C3D08A46AQ50717808-9A9630B0-CB50-4D30-800A-A35C727CB239Q53343875-498CD5B0-C359-430B-B6CB-EC7CCE28E6BAQ53580759-98D4CB38-C1F2-464A-A98E-42E1662812D4Q57100222-6A9B4776-5CCA-41D9-AB25-8D1F3CCB6A0B
P2860
Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Intravenous busulphan for cond ...... ood stem cell transplantation.
@en
Intravenous busulphan for cond ...... ood stem cell transplantation.
@nl
type
label
Intravenous busulphan for cond ...... ood stem cell transplantation.
@en
Intravenous busulphan for cond ...... ood stem cell transplantation.
@nl
prefLabel
Intravenous busulphan for cond ...... ood stem cell transplantation.
@en
Intravenous busulphan for cond ...... ood stem cell transplantation.
@nl
P2093
P2860
P1476
Intravenous busulphan for cond ...... ood stem cell transplantation.
@en
P2093
F Kroschinsky
G Ehninger
M Bornhäuser
U D Renner
U S Schuler
P2860
P304
P356
10.1046/J.1365-2141.2001.03044.X
P407
P577
2001-09-01T00:00:00Z